Fig. 2

MLH1 affected endometrial carcinoma cell proliferation in response to cisplatin in vitro. a RL95–2 and Ishikawa cell growth curves after 24 h, 48 h and 72 h of treatment with different concentrations of cisplatin (0–25 μmol). b Viability rates of RL95–2 cells after MLH1 silencing. Cells transfected with siMLH1-NC and normal RL95–2 cells served as controls. c Viability rates of Ishikawa cells after MLH1 overexpression. The viability rate of ADV-MLH1/ADV-NC-infected Ishikawa cells was normalized to control cells. Each value represents the mean of at least three independent experiments performed in triplicate (CCK-8). d Distribution of the cell cycle in response to 5 μmol cisplatin in MLH1 knockdown RL95–2 cells compared with the control. e Distribution of the cell cycle in response to 25 μmol cisplatin in MLH1-overexpressing cells compared with the control